$ENVB News

Enveric Biosciences Reports Favorable Preclinical Results for Non-Hallucinogenic Psychiatric Candidate

Enveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET Studies

Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Enveric Biosciences Receives U.S. Patent Office Notice Of Allowance For An Application Covering Novel Compounds Within Its EVM401 Series Of Drug Candidates

Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

Enveric Biosciences Q2 EPS $(0.76) Up From $(11.64) YoY

Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003

Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Candidate

Enveric Biosciences Announces New Preclinical Data That Further Supports The Non-Hallucinogenic Profile Of EB-003; GloSensor Assay Findings Align With Previously Reported BRET Data

Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development

Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

Enveric Biosciences Announces Participation in 2026 BIO International Convention

Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day

Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003

Enveric Biosciences Initiates Investigational New Drug-enabling Genotoxicity Studies Of EB-003

Enveric Biosciences Q1 EPS $(1.08) Up From $(14.64) YoY

Enveric Highlights Preclinical PTSD Data Amid Rising Focus On Mental Health Therapies

Enveric Biosciences Highlights Results for EB-003 In PTSD Preclinical Model; Says Previously Reported Results Support Continued Development Of EB-003 For PTSD, Other Neuropsychiatric Condition

Enveric Biosciences shares are trading higher after the FDA announced accelerated efforts to advance treatments for serious mental illnesses, following an executive order signed by President Trump.